Bepreve Approval History

• FDA approved: Yes (First approved September 8th, 2009)
• Brand name: Bepreve
• Generic name: bepotastine
• Company: ISTA Pharmaceuticals, Inc.
• Treatment for: Conjunctivitis, Allergic

Bepreve (bepotastine ophthalmic solution) is an antihistamine and mast cell stabilizer for treatment of the symptoms of allergic conjunctivitis.

FDA Approval History for Bepreve

Date	Article
Sep  9, 2009	Ista Pharmaceuticals' Bepreve Receives FDA Approval for the Treatment of Ocular Itching Due to Allergies
Jun 28, 2009	Dermatologic and Ophthalmic Drugs Advisory Committee Unanimously Recommends Bepreve for the Treatment of Ocular Itching Associated with Allergic Conjunctivitis
Jun  2, 2009	ISTA Pharmaceuticals Announces FDA Advisory Committee to Review Bepreve for the Treatment of Ocular Itching Associated with Allergic Conjunctivitis
Jan 15, 2009	ISTA Pharmaceuticals' New Drug Application for Bepreve Accepted for Review by U.S. Food and Drug Administration
Nov 14, 2008	ISTA Pharmaceuticals Files New Drug Application with U.S. FDA for Bepreve

See also...

Bepreve (bepotastine) Consumer Information

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.